DB:47M

Stock Analysis Report

Executive Summary

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America and the Caribbean, Europe, and the Asia Pacific.


Snowflake Analysis

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has MedMira's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 47M's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

47M

-4.6%

DE Medical Equipment

-5.7%

DE Market


1 Year Return

650.0%

47M

19.7%

DE Medical Equipment

6.1%

DE Market

Return vs Industry: 47M exceeded the German Medical Equipment industry which returned 19.7% over the past year.

Return vs Market: 47M exceeded the German Market which returned 6.1% over the past year.


Shareholder returns

47MIndustryMarket
7 Day0%-4.6%-5.7%
30 Day-28.6%-10.7%-5.7%
90 Day7.1%-5.4%-3.6%
1 Year650.0%650.0%21.5%19.7%9.3%6.1%
3 Year-6.3%-6.3%125.6%119.8%8.9%-0.7%
5 Year-65.9%-65.9%254.0%236.6%13.6%-2.0%

Price Volatility Vs. Market

How volatile is MedMira's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is MedMira undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether MedMira is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MedMira has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of 47M’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through MedMira regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is MedMira forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MedMira has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has MedMira performed over the past 5 years?

12.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 47M is currently unprofitable.

Growing Profit Margin: 47M is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 47M is unprofitable, but has reduced losses over the past 5 years at a rate of 12.9% per year.

Accelerating Growth: Unable to compare 47M's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 47M is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17%).


Return on Equity

High ROE: 47M's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is MedMira's financial position?


Financial Position Analysis

Short Term Liabilities: 47M has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 47M has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 47M has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 47M's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 47M has a high level of physical assets or inventory.

Debt Coverage by Assets: 47M has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 47M has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 47M has less than a year of cash runway if free cash flow continues to grow at historical rates of 25.3% each year.


Next Steps

Dividend

What is MedMira's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 47M's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 47M's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 47M's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 47M's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 47M's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.4yrs

Average management tenure


CEO

Hermes Chan 0

13.6yrs

Tenure

CA$191,228

Compensation

Mr. Hermes Chan Co-Founded MedMira Inc. and has been its President since 2000 and Chief Executive Officer since July 24, 2006. Mr. Chan has been the Chief Executive Officer and President of MedMira Laborat ...


CEO Compensation Analysis

Compensation vs Market: Hermes's total compensation ($USD143.91K) is below average for companies of similar size in the German market ($USD415.76K).

Compensation vs Earnings: Hermes's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Hermes Chan
Co-Founder13.6yrsCA$191.23k0.43% CA$38.9k
Markus Meile
Chief Financial Officer5.6yrsCA$149.53kno data
Stewart McKelvey
Legal Counsel0yrsno datano data
Kevin Jones
Head of Commercialization and Senior Director of Sales & Marketing6.4yrsno datano data

6.4yrs

Average Tenure

Experienced Management: 47M's management team is seasoned and experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MedMira Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MedMira Inc.
  • Ticker: 47M
  • Exchange: DB
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$13.167m
  • Listing Market Cap: CA$9.108m
  • Shares outstanding: 658.36m
  • Website: https://www.medmira.com

Location

  • MedMira Inc.
  • 155 Chain Lake Drive
  • Suite 1
  • Halifax
  • Nova Scotia
  • B3S 1B3
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MIRTSXV (TSX Venture Exchange)YesCommon SharesCACADMar 2000
47MDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2000
MMIR.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2000

Biography

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America and the Caribbean, Europe, and the Asia Pacific. The company’s research is focused on specific areas of the diagnostics market, such as rapid, point-of-care, and in vitro sectors. It offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. The company also provides Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; and Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis. In addition, it offers Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics. MedMira Inc. sells its products through a network of medical distributors and strategic business development partners with customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 21:39
End of Day Share Price2020/02/25 00:00
Earnings2019/10/31
Annual Earnings2019/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.